Curie Brief
Turn on cookies to sign in
Signing in saves your progress to your Curie account. We can only do that with cookies on — turn them on to continue.
News
A UK policy shift away from routine P2Y12 inhibitor pretreatment in non-ST-elevation acute coronary syndrome patients comes with a real trade-off. While bleeding events dropped significantly, the odds of suffering an in-hospital STEMI more than quadrupled. Longer waits for coronary angiography made the STEMI risk even worse, raising questions about whether global trial evidence translates to UK healthcare realities.
A UK policy change that moved away from routinely giving patients a P2Y12 inhibitor (a blood-thinning drug) before coronary angiography has revealed a significant clinical trade-off. A retrospective study of over 2,500 patients with non-ST-elevation acute coronary syndrome (NSTE-ACS) found that skipping the pretreatment dramatically reduced bleeding — but also sharply increased the risk of in-hospital heart attacks (STEMI).
The study, published in Open Heart, compared two patient cohorts treated under different policies at a tertiary cardiac centre in England between 2021 and 2023. The median wait time for coronary angiography was 3.6 days — notably longer than the timelines used in the clinical trials that informed current guidelines.
This study highlights that clinical trial evidence doesn't always translate neatly into real-world healthcare systems. In the UK, where angiography wait times are longer than trial benchmarks, withholding P2Y12 pretreatment may leave patients vulnerable to heart attacks. Clinicians and policymakers may need to tailor antiplatelet strategies to local healthcare capacity.
